scholarly journals Transferrin receptor is another receptor for SARS-CoV-2 entry

2020 ◽  
Author(s):  
Ren Lai ◽  
Xiaopeng Tang ◽  
Mengli Yang ◽  
Zilei Duan ◽  
Zhiyi Liao ◽  
...  

Abstract Angiotensin-converting enzyme 2 (ACE2) has been suggested as a receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry to cause coronavirus disease 2019 (COVID-19). However, no ACE2 inhibitors have shown definite beneficiaries for COVID-19 patients, applying the presence of another receptor for SARS-CoV-2 entry. Here we show that ACE2 knockout dose not completely block virus entry, while TfR directly interacts with virus Spike protein to mediate virus entry and SARS-CoV-2 can infect mice with over-expressed humanized transferrin receptor (TfR) and without humanized ACE2. TfR-virus co-localization is found both on the membranes and in the cytoplasma, suggesting SARS-CoV-2 transporting by TfR, the iron-transporting receptor shuttling between cell membranes and cytoplasma. Interfering TfR-Spike interaction blocks virus entry to exert significant anti-viral effects. Anti-TfR antibody (EC50 ∼16.6 nM) shows promising anti-viral effects in mouse model. Collectively, this report indicates that TfR is another receptor for SARS-CoV-2 entry and a promising anti-COVID-19 target.

2020 ◽  
Author(s):  
Xiaopeng Tang ◽  
Mengli Yang ◽  
Zilei Duan ◽  
Zhiyi Liao ◽  
Lei Liu ◽  
...  

AbstractAngiotensin-converting enzyme 2 (ACE2) has been suggested as a receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry to cause coronavirus disease 2019 (COVID-19). However, no ACE2 inhibitors have shown definite beneficiaries for COVID-19 patients, applying the presence of another receptor for SARS-CoV-2 entry. Here we show that ACE2 knockout dose not completely block virus entry, while TfR directly interacts with virus Spike protein to mediate virus entry and SARS-CoV-2 can infect mice with over-expressed humanized transferrin receptor (TfR) and without humanized ACE2. TfR-virus co-localization is found both on the membranes and in the cytoplasma, suggesting SARS-CoV-2 transporting by TfR, the iron-transporting receptor shuttling between cell membranes and cytoplasma. Interfering TfR-Spike interaction blocks virus entry to exert significant anti-viral effects. Anti-TfR antibody (EC50 ~16.6 nM) shows promising anti-viral effects in mouse model. Collectively, this report indicates that TfR is another receptor for SARS-CoV-2 entry and a promising anti-COVID-19 target.


2020 ◽  
Vol 8 (12) ◽  
pp. 1894
Author(s):  
Matteo Gasbarri ◽  
Philip V’kovski ◽  
Giulia Torriani ◽  
Volker Thiel ◽  
Francesco Stellacci ◽  
...  

Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) depends on angiotensin converting enzyme 2 (ACE2) for cellular entry, but it might also rely on attachment receptors such as heparan sulfates. Several groups have recently demonstrated an affinity of the SARS-CoV2 spike protein for heparan sulfates and a reduced binding to cells in the presence of heparin or heparinase treatment. Here, we investigated the inhibitory activity of several sulfated and sulfonated molecules, which prevent interaction with heparan sulfates, against vesicular stomatitis virus (VSV)-pseudotyped-SARS-CoV-2 and the authentic SARS-CoV-2. Sulfonated cyclodextrins and nanoparticles that have recently shown broad-spectrum non-toxic virucidal activity against many heparan sulfates binding viruses showed inhibitory activity in the micromolar and nanomolar ranges, respectively. In stark contrast with the mechanisms that these compounds present for these other viruses, the inhibition against SARS-CoV-2 was found to be simply reversible.


2020 ◽  
Author(s):  
Cecylia S. Lupala ◽  
Vikash Kumar ◽  
Xuanxuan Li ◽  
Xiao-dong Su ◽  
Haiguang Liu

ABSTRACTThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19, is spreading globally and has infected more than 3 million people. It has been discovered that SARS-CoV-2 initiates the entry into cells by binding to human angiotensin-converting enzyme 2 (hACE2) through the receptor binding domain (RBD) of its spike glycoprotein. Hence, drugs that can interfere the SARS-CoV-2-RBD binding to hACE2 potentially can inhibit SARS-CoV-2 from entering human cells. Here, based on the N-terminal helix α1 of human ACE2, we designed nine short peptides that have potential to inhibit SARS-CoV-2 binding. Molecular dynamics simulations of peptides in the their free and SARS-CoV-2 RBD-bound forms allow us to identify fragments that are stable in water and have strong binding affinity to the SARS-CoV-2 spike proteins. The important interactions between peptides and RBD are highlighted to provide guidance for the design of peptidomimetics against the SARS-CoV-2.


2020 ◽  
Vol 1 (2) ◽  
pp. 70-76
Author(s):  
Risma Ikawaty

Abstract— Background: A human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is known to be responsible for coronavirus disease 2019 (COVID-19). Pulmonary complications has been considered as the classical clinical manifestations until symptoms on the extra-pulmonary organs may also occur recently, which might be linked to the presence of angiotensin-converting enzyme 2 (ACE2) receptor. Objective: This article evaluates clinical manifestation of COVID-19 and the presence of ACE2 receptor by looking at its interaction to SARS-CoV-2. Methods: 27 articles in English have been selected through search engine PubMed and Google Scholar by using specific keywords. These articles include research journals, case report, systematic review and meta-analysis, and textbooks. Result: Pathogenesis of COVID-19 begins with the binding of spike protein SARS-CoV-2 to ACE2 receptor of host cells. Clinical manifestation of COVID-19 is no longer limited to the pulmonary system but also extra-pulmonary systems since ACE2 receptor abundantly distributed on the other organs. Further, genetic variations of region binding protein of viral spike protein and ACE2 receptor may predispose clinical manifestation of COVID19.  Conclusions: Dynamic interplay between SARS-CoV-2 and receptor ACE2 has great implication to the clinical symptoms. Genetic variation of spike protein SARS-CoV-2 play role not only for cross transmission but also its virulence, while genetic variation of human receptor ACE2 influences its susceptibility or resistance against the infection. Keywords: ACE2 receptor, Coronavirus Diseases-19, clinical manifestation, SARS-CoV-2, genetic variation. Abstrak— Virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) merupakan penyebab utama dari coronavirus disease 2019 (COVID-19). Komplikasi pernapasan diangap sebagai gejala klinis klasik hingga akhirnya timbul berbagai manifestasi klinis di organ lain sebagai gejala awal COVID19. Hal ini kemudian dihubungkan dengan reseptor angiotensin-converting enzyme 2 (ACE2). Artikel ini mengevaluasi manifestasi klinis yang disebabkan  interaksi antara reseptor ACE2 dan SARS-CoV-2. PubMed dan Google Scholar digunakan untuk mencari artikel dengan kata kunci yang spesifik untuk COVID-19, SARS-CoV-2, reseptor ACE2, variasi genetik, dan manifestasi klinisnya. Dua puluh tujuh artikel berbahasa Inggris yang digunakan termasuk jurnal penelitian, laporan kasus, systematic review, meta-analysis, dan buku teks. Patogenesis COVID19 dimulai dengan ikatan protein Spike SARS-CoV-2 dan reseptor ACE2. Studi memperlihatkan bahwa reseptor ACE2 ditemui di berbagai jaringan/organ selain organ sistem respirasi sehingga memperlihatkan gejala klinis yang berbeda. Selain itu variasi genetik yang terdapat pada protein spike dari virus dan reseptor ACE2 juga merupakan faktor penting pada terjadinya COVID19. Penulis menyimpulkanbahwa dinamika interaksi antara reseptor ACE2 dan protein spike SARS-CoV-2 termasuk variasi genetic, keduanya memegang peranan penting terhadap suseptibilitas/resistensi dan manifestasi klinis COVID19. Kata kunci: Coronavirus Diseases-19, manifestasi klinis,  reseptor ACE2, SARS-CoV-2, variasi genetik.


2020 ◽  
Vol 21 (21) ◽  
pp. 8268
Author(s):  
Gennady Verkhivker

Binding to the host receptor is a critical initial step for the coronavirus SARS-CoV-2 spike protein to enter into target cells and trigger virus transmission. A detailed dynamic and energetic view of the binding mechanisms underlying virus entry is not fully understood and the consensus around the molecular origins behind binding preferences of SARS-CoV-2 for binding with the angiotensin-converting enzyme 2 (ACE2) host receptor is yet to be established. In this work, we performed a comprehensive computational investigation in which sequence analysis and modeling of coevolutionary networks are combined with atomistic molecular simulations and comparative binding free energy analysis of the SARS-CoV and SARS-CoV-2 spike protein receptor binding domains with the ACE2 host receptor. Different from other computational studies, we systematically examine the molecular and energetic determinants of the binding mechanisms between SARS-CoV-2 and ACE2 proteins through the lens of coevolution, conformational dynamics, and allosteric interactions that conspire to drive binding interactions and signal transmission. Conformational dynamics analysis revealed the important differences in mobility of the binding interfaces for the SARS-CoV-2 spike protein that are not confined to several binding hotspots, but instead are broadly distributed across many interface residues. Through coevolutionary network analysis and dynamics-based alanine scanning, we established linkages between the binding energy hotspots and potential regulators and carriers of signal communication in the virus–host receptor complexes. The results of this study detailed a binding mechanism in which the energetics of the SARS-CoV-2 association with ACE2 may be determined by cumulative changes of a number of residues distributed across the entire binding interface. The central findings of this study are consistent with structural and biochemical data and highlight drug discovery challenges of inhibiting large and adaptive protein–protein interfaces responsible for virus entry and infection transmission.


2021 ◽  
Author(s):  
Hang Yang ◽  
Xiaohui Zhao ◽  
Meng Xun ◽  
Lingjie Xu ◽  
Bing Liu ◽  
...  

AbstractThe recent COVID-19 pandemic poses a global health emergency. Cellular entry of the causative agent SARS-CoV-2 is mediated by its spike protein interacting with cellular receptor- human angiotensin converting enzyme 2 (ACE2). Here, we used lentivirus based pseudotypes bearing spike protein to demonstrate that entry of SARS-CoV-2 into host cells is dependent on clathrin-mediated endocytosis, and phosphoinositides play essential role during this process. In addition, we showed that the intracellular domain and the catalytic activity of ACE2 is not required for efficient virus entry. These results provide new insights into SARS-CoV-2 cellular entry and present potential targets for drug development.


Sign in / Sign up

Export Citation Format

Share Document